智通财经APP获悉，云顶新耀-B(01952)早盘涨近5%，截至发稿，涨4.11%，报37.96港元，成交额4956.24万港元。
消息面上，3月13日，云顶新耀宣布，其在研眼科管线VIS-101治疗湿性年龄相关性黄斑变性（湿性AMD）的IIa期研究取得积极顶线数据。基于此次IIa期积极的临床数据，VIS-101计划于2026年下半年启动IIb期临床研究，并于2027年启动全球III期临床研究。
值得注意的是，3月9日，云顶新耀宣布，旗下自身免疫性疾病领域核心产品维适平（精氨酸艾曲莫德片，VELSIPITY）中国大陆首张处方于中山大学附属第一医院开出，标志着这款创新疗法正式进入中国临床应用阶段。维适平也已同步在广州、上海、杭州、西安、重庆、北京和南京7个核心城市的8家三甲医院同步开出处方，实现上市首日即覆盖全国重点区域患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.